Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
Healthcare
$1.77 +2.65%
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
52W Low $1.66High $4.54
Volume 1.99M
Average 2.06M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$165.24M
FY 2025 · Annual
Investing Cash Flow
$138.67M
FY 2025 · Annual
-14.5% YoYFinancing Cash Flow
$40.47M
FY 2025 · Annual
-27.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 43.4M | 29.29M | 19.8M | 21.42M | 10M |
| Change in Working Capital | (21.41M) | 8.18M | (1.59M) | 3.45M | (31.23M) |
| Accounts Receivables | 5.78M | (4.88M) | (5.04M) | (6.08M) | 1.09M |
| Inventory | (3.35M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.14M) | 4.37M | (1.49M) | (2.29M) | (2.89M) |
| Other Working Capital | (22.71M) | 8.69M | 4.94M | 11.82M | (29.43M) |
| Other Non-Cash Items | 1.66M | (724K) | (3.23M) | (3.87M) | 10.77M |
| Operating Cash Flow | (163.8M) | (177.35M) | (132.18M) | (210.28M) | (165.24M) |
| Capital Expenditures | (7.98M) | (4.12M) | (4.72M) | (8.83M) | (607K) |
| Acquisitions (Net) | 46.49M | 18K | 0 | 0 | 269K |
| Purchases of Investments | (408.89M) | (315.19M) | (258.52M) | (86.22M) | 0 |
| Sales of Investments | 362.4M | 433.35M | 259.51M | 257.19M | 139.01M |
| Other Investing Activities | (46.49M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.47M) | 114.07M | (3.73M) | 162.15M | 138.67M |
| Debt Repayment | 0 | 0 | 0 | 0 | (2.87M) |
| Common Stock Issued | 249.46M | 1.28M | 117.08M | 56.03M | 43.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.65M | 0 | 960K | 0 | 0 |
| Financing Cash Flow | 282.11M | 1.28M | 118.04M | 56.03M | 40.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 63.84M | (62M) | (17.87M) | 7.89M | 13.9M |
| Free Cash Flow | (171.78M) | (181.47M) | (136.9M) | (219.11M) | (165.85M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$160.1M
+ D&A$5.3M
+ Stock-Based Comp$10.0M
+ Deferred Tax$0
- Working Capital-$31.2M
+ Other Non-Cash$10.8M
= Operating Cash Flow-$165.2M
- Capex-$607.0K
= Free Cash Flow-$165.8M
Analysis
FY2025 free cash flow is -$165.8M. FCF conversion is 103.6% of net income. Operating cash flow was -$165.2M, with capex of -$607.0K. The largest bridge item is Working Capital at -$31.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
Does EDIT generate free cash flow?
Editas Medicine, Inc. (EDIT) generated -$165.85M of free cash flow in fiscal 2025.
How much operating cash flow does EDIT produce?
Operating cash flow was -$165.24M, before capital expenditures of $607,000.00.
Continue the stock analysis
Jump to another research area for this company.